Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) Director Bruce Polsky sold 18,252 shares of Atea Pharmaceuticals stock in a transaction on Wednesday, November 18th. The shares were sold at an average price of $3.95, for a total transaction of $72,095.40. Following the completion of the sale, the director directly owned 158,580 shares in the company, valued at $626,391. This represents a 10.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Bruce Polsky also recently made the following trade(s):
- On Thursday, November 19th, Bruce Polsky sold 8,750 shares of Atea Pharmaceuticals stock. The stock was sold at an average price of $4.03, for a total value of $35,262.50.
- On Monday, November 16th, Bruce Polsky sold 14,254 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $4.27, for a total value of $60,864.58.
- On Tuesday, November 17th, Bruce Polsky sold 8,720 shares of Atea Pharmaceuticals stock. The stock was sold at an average price of $4.03, for a total value of $35,141.60.
Atea Pharmaceuticals Stock Performance
NASDAQ AVIR opened at $3.97 on Friday. The business has a fifty day moving average price of $4.65 and a 200 day moving average price of $4.94. The company has a market cap of $318.79 million, a P/E ratio of -2.04 and a beta of 0.76. Atea Pharmaceuticals, Inc. has a one year low of $2.92 and a one year high of $6.45.
Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.11. As a group, sell-side analysts predict that Atea Pharmaceuticals, Inc. will post -1.60 EPS for the current fiscal year.
Hedge Funds Weigh In On Atea Pharmaceuticals
Institutional investors have recently made changes to their positions in the stock. Empowered Funds LLC purchased a new position in shares of Atea Pharmaceuticals in the third quarter worth approximately $475,000. Engineers Gate Manager LP acquired a new stake in shares of Atea Pharmaceuticals during the second quarter valued at approximately $78,000. Spark Investment Management LLC purchased a new stake in shares of Atea Pharmaceuticals in the 2nd quarter valued at approximately $75,000. Headlands Technologies LLC purchased a new stake in shares of Atea Pharmaceuticals in the 2nd quarter valued at approximately $77,000. Finally, Wellington Management Group LLP boosted its stake in Atea Pharmaceuticals by 262.7% in the 2nd quarter. Wellington Management Group LLP now owns 206,785 shares of the company’s stock worth $962,000 after purchasing an additional 149,776 shares during the period. 86.67% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several equities analysts have commented on AVIR shares. Wall Street Zen raised shares of Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Morgan Stanley upped their price objective on Atea Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Monday, November 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.00.
Check Out Our Latest Stock Report on AVIR
Atea Pharmaceuticals Company Profile
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company’s investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.
Read More
- Five stocks we like better than Atea Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
